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Summary 
Expression of a novel thymocyte differentiation antigen, JL1, defined by a monodonal antibody 
(mAb) developed against human thymocytes showed a specificity for stage II double positive 
(CD4+CD8 +) human cortical thymocytes. This antigen was not expressed at detectable levels 
on medullary thymocytes, mature peripheral leukocytes, bone marrow cells or on other types 
of tissues elsewhere in the human body. Immunohistologic analysis revealed that JL1 had a clear 
pattern of distribution on cortical thymocytes. Immunoprecipitation of 12SI-labded cell lysates 
from human thymocytes and Molt-4 leukemic cell line with anti-JL1 mAb yielded a 120-130-kD 
single chain glycoprotein. When immunoprecipitation of cell lysate was done after endoglycosidase 
F treatment, JL1 antigen was still  detected by antibody but the band showed a reduction in 
apparent  molecular  mass  of "~  kD.  This  suggests  that,  although JL1  molecule contains 
carbohydrate group, this does not form a critical part of the antigenic determinant for anti-JL1 
antibody. JL1 antigen appears to be the first double positive, stage-specific differentiation antigen 
of human thymocyte reported so far. This antigen would be a useful marker for lymphoblastic 
malignancy of stage II thymocyte origin and it may be involved in the thyrnocyte education process. 
I 
ntrathymic T cell development entails a complex series of 
proliferation, differentiation, and selection events (1, 2). 
This sequence of events has been mapped according to the 
expression of specific combinations of cell surface differentia- 
tion antigens. However, the major cell surface molecules to 
compartmentalize the subpopulations of human thymocytes, 
including CD1,  CD3,  CD4, and CD8, do not specifically 
define discrete stages in T cell differentiation (3). The involve- 
ment of the TCR-CD3 complex is imperative for selection 
events, and there are several key steps in T cell development, 
such as lineage commitment, induction and expression of TCR 
gene rearrangements, and education events for positive and 
negative selections (2).  Clearly, for a better understanding 
of the mechanisms controlling T cell differentiation, it is im- 
portant to identify new molecules on the surface of these cells 
as a prelude to determining their functional relevance. In this 
report, we introduce a novel stage II-specific human thymo- 
cyte differentiation antigen, JL1, that was detected by a murine 
mAb developed against human thymocytes. This specificity 
for stage II thymocytes was shown by flow cytometry and 
immunohistochemical analysis. Immunopredpitation and SDS- 
PAGE analysis demonstrated that anti-JL1 mAb recognized 
a single chain glycoprotein with a molecular mass of 120-130 
kD with relatively short carbohydrate residues determined 
by endoglycosidase F (endo-F) treatment of lysates from human 
thymocytes and Molt-4 T leukemic cells. Given the unique 
T  cell stage specificity of the JL1 molecule, it is likely that 
this antigen is involved in a T cell education program during 
thymic ontogeny. 
Materials and Methods 
Cells and Tissues.  Human thymocytes were collected from frag- 
ments of thymuses that had been removed for the exposure of the 
heart during corrective cardiac surgery of 1-12-mo-old patients. 
Single cell suspensions were prepared, washed, and used for immu- 
nization and screening.  Human leukemic  cell lines used for screening 
included Molt-4, Molt-3, CCRF-CEM, H9, Hut-78, Dandi, KG-1, 
U937, and THP-1. PBMC were isolated from peripheral blood of 
normal human volunteers. Lymphocytes were incubated in KPMI- 
1640 containing  10% fetal bovine serum with or without PHA 
(GIBCO-BRL, Gaithersburg, MD), FWM (Boehringer Mannheim 
Biochemicals, Mannheim, Germany), or anti-CD3 mAb (OKT3; 
American Type Culture Collection, R_ockviUe,  MD). Cultures were 
collected on day 3 for PHA and anti-CD3 mAb and on day 5 for 
PWM. Activation of cells was confirmed by [3H]thymidine incor- 
poration, expression of activation-related molecules such as HLA- 
DR and IL-2K, and morphological identification of blast forma- 
tion under light microscopic  examination (data not shown). Normal 
bone marrow samples were obtained from Seoul National Univer- 
sity Children's Hospital and were also used for screening. Mouse 
L cells transfected with full-length cDNA of CDla, CDlb, and 
CDlc were kind gifts ofC. Terhorst (Beth Israel Hospital, Boston, 
MA) (4). 
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munized with 107 human  thymocytes at 2-wk intervals for 2 mo, 
the spleen was removed, and 10  s spleen cells were fused with 107 
SP2/0-Ag14 mouse myeloma cells using polyethylene glycol (PEG 
4000; Rahway, NJ) (5). One of the resulting  hybridoma  clones, 
whose supematants were reactive to human thymocytes, was named 
anti-JL1. The isotype of anti-JL1 mAb determined by enzyme im- 
munoassay using ScreenType  TM (Boehringer Mannheim Biochem- 
icals) was IgG1. 
Immunohistocheraical Study.  Snap-frozen sections of fetal and 
postnatal thymus, lymph node, tonsil, spleen, cerebrum, skin, and 
other tissues  were incubated with anti-JL1 mAb, followed  by purified 
biotinylated goat anti-mouse IgG, IgA, and IgM, and then by strep- 
tavidin-horseradish peroxidase  conjugate after washing. The staining 
pattern  was analyzed based on serial hematoxylin-eosin  stained 
sections. 
lmmunofluorescence  Assay.  Fresh  cell suspensions of human fetal 
and postnatal thymocytes, PBL, bone marrow cells, and tumor cell 
lines were prepared, stained by indirect immunofluorescence  method 
with anti-JL1 mAb followed by FITC-conjugated i~oat anti-mouse 
Ig,  and analyzed by a flow cytometer  (FACScan  ~, Becton Dick- 
inson  & Co.,  Mountain  View, CA). 
Comparative  analysis of JD1 positive and negative thymocytes 
with those expressing and nonexpressing CDla was performed along 
with their expression pattern of CD4 and CD8. Thymocytes were 
fractionated on the basis of the reactivity with anti-JL1 mAb and 
anti-CDla by panning procedure. Enriched JLI+/-  and CDla + / - 
cells were analyzed by double-fluorescence FACS  |  analysis. Both 
types of cells were first stained with FITC-conjugated  anti-CD4 
mAb and subsequently stained with PE-conjugated anti-CD8 mAb 
(Becton Dickinson  & Co.). 
Iramunoprecipitation of  JLl  Antigen.  Human  thymocytes  and 
Moh-4 tumor cells were surface labeled with Na12SI (1 mCi/4  x 
107 cells) using  lactoperoxidase-catalyzed iodination.  The  cells 
were then lysed in 4 ml of lysis buffer containing  0.5% (wt/vol) 
NP-40. The lysates were precleared several  times by using an irrele- 
vant ascites of IgGl-type antibody conjugated to protein A-Sepharose 
CL4B beads. Immunoprecipitation  was performed by mixing  of 
radiolabeled  cell  lysate  with  anti-JL1  mAb-conjugated  protein 
A-Sepharose CL4B beads and incubating  at 4~  overnight.  For 
endo-F  (Boehringer  Mannheim  Biochemicals)  treatments,  the 
washed beads were resuspended in 20 mM potassium phosphate 
buffer, pH 7.4, containing 0.2% SDS and incubated with endo-F 
2 unit overnight at 37~  The supernatant  eluted from the beads 
was collected and SDS-PAGE was carried out on 8 or 10% poly- 
acrylamide gels. 
Results  and  Discussion 
In this report, we describe a novel 120-130-kD human T 
cell surface molecule, designated JL1, which was strongly and 
specifically expressed on stage II cortical thymocytes of human 
origin  and some leukemic T  cell lines. 
To study the detailed pattern of expression of  JL1 antigen 
on lymphoid and nonlymphoid  tissues, we performed im- 
munohistochemical analysis using fresh tissues obtained from 
surgically removed materials including tonsil, lymph node, 
spleen, cerebrum, cerebellum, skin, lung, esophagus, stomach, 
small and large intestine,  appendix,  liver,  pancreas,  kidney, 
urinary bladder, testis, ovary, uterus, and adrenal gland (data 
not  shown). JL1 antigen  was absent in all  types of tissues 
examined other than human thymocytes, indicating that JL1 
Figure  1.  Immunohistologic  localization of  JL1 antigen in the thymus. 
Snap-frozen section of human thymus from a 5-mo-old patient was in- 
cubated with anti-JL1 mAb, then with biotinylated anti-mouse Ig, and 
streptavidin-peroxidase conjugate followed by  freshly prepared 3,3- 
diaminobenzidine solution. Corte~ (C, cortical  thymocytes)  shows  intense 
positive staining in contrast with the medulla (M). x40. 
antigen has an extreme specificity for human thymocytes. Even 
in the thymus, localization of this antigen was confined to 
cortical thymocytes (Fig.  1). In addition to investigating the 
thymic reactivity of anti-JL1 mAb, we also looked at the ex- 
pression of this antigen on various hematopoietic cells by in- 
direct immunofluorescence staining and flow cytometry. As 
with mature medullary thymocytes, PBMC from blood and 
Table  1.  Distribution  of  JL1 Antigen on Normal  Hematopoietic Cells 
Determined by Indirect Immunofluorescence and Flow Cytometric 
Analysis 
Number of  Proportion  of 
Cells  cases  JL1 + cells 
% 
Thymocytes 
Prenatal  16-21  wk  4 
22-27 wk  5 
28-33 wk  2 
Postnatal  6 
Spleen cells  4 
Bone marrow cells  6 
PBMC  54 
Activated  PBMC 
PHA (10/~g/ml)  5 
PWM (3 /~g/ml)  5 
anti-CD3  5 
(0.5  /~g/ml) 
82+9* 
90_+  5 
96+3 
91_+6 
m 
* Mean _+ SD. 
* <5%. 
1448  JL1, a Novel Differentiation Antigen of Human Cortical Thymocyte Figure  2.  SDS-PAGE  analysis of surface molecules immunoprecipitated 
by anti-JI.1 mAb from thymocytes (a) and Molt-4 tumor cells (b). Cells 
(5  x  106)  were surface labeled with 12sI-  using lactoperoxidase technique, 
and lysed in buffer containing 0.5% NP-40. Immunoprecipitation  was per- 
formed by anti-JL1 mAb coupled to protein A-Sepharose beads. SDS-PAGE 
analysis was performed under reducing (R) and nonreducing  (NR) condi- 
tions using  10%  (a) or 8% (b) polyacrylamide gels. SDS-PAGE analysis 
was also clone under reducing  and nonreducing conditions  after endo-F 
treatment  of antigen-bound beads (endo.F). 
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Figure  3.  FACS  |  analysis of human thymocytes 
shows the single histogram  ofJI.1 (a) and CDla 
(b)  from total  thymocytes  and the distribution 
profiles of CD4 and CD8 on thymocytes selected 
for the expression of JI.1 (c and e) and CDla (d 
and  f) antigens using panning procedure. The ad- 
herent  (c and d) and nonadherent  cells (e and f) 
were stained  with FITC-conjugated anti-CD4 mAb 
and PE-conjugated  anti-CD8 mAb. 
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Percent positive cells 
Category  Cell line  CDla  CDlb  CDlc  JL1 
T  cell  Molt-3  93  100  97  100 
Molt-4  98  74  95  100 
CCP..F-CEM  -*  -  -  62 
H-9  .... 
Hut-78  .... 
B cell  Daudi  .... 
Monocyte  U937  NT~  NT  NT  - 
THP-1  NT  NT  NT  - 
Myelocyte  KG-1  NT  NT  NT  - 
*  <5%. 
* NT,  not tested. 
spleen were  JL1 negative. Even when PBL were activated with 
PHA, PWM, or anti-CD3 mAb, there was no dear JL-1 posi- 
tivity suggesting that this marker is no longer expressed on 
peripheral lymphoid cells (Table 1). JL1 appears to be specific 
to immature cortical thymocyte and distinct from other well- 
known cortical thymocyte differentiation antigens and acti- 
vation molecules reported so far. 
For biochemical characterization of cell surface antigen rec- 
ognized by anti-JL1 mAb, Molt-4 leukemic cells and human 
thymocytes were iodinated using lactoperoxidase, and im- 
munoprecipitates of NP-40 solubilized cell lysates were ana- 
lyzed by SDS-PAGE.  As shown in Fig. 2, a and b, anti-JL1 
mAb precipitated a single chain glycoprotein of apparent mo- 
lecular mass 120-130 kD with short carbohydrate residues 
determined by endo-F treatment (Fig. 2). The reduced form 
migrated more slowly than the nonreduced form, suggesting 
the presence of intramolecular disulfide bridge. The molec- 
ular weight of  JL1 determined from Molt-4 was slightly greater 
than that from thymocytes, suggesting some differences in 
the extent of glycosylation. The epitope recognized by anti- 
JL1 mAb seemed not to be a carbohydrate moiety since im- 
munopredpitation of Molt-4 cell lysate pretreated with endo-F 
yielded an identical band to that of immunoprecipitate digested 
with endo-F after antigen elution (data not shown). 
There are a number of findings that JL1 seems to define 
a novel differentiation antigen of immature thymocytes dis- 
tinct from thymocyte differentiation antigens of CD1 family. 
First, the biochemical nature of  JL1 is entirely different from 
that of CD1 antigens, the latter being composed of a H chain 
of 43-49 kD and Bz-microglobulin (/~2m) of 12 kD. Second, 
cell and tissue distribution of JL1 is highly specific. JL1 an- 
tigen is expressed on the cell surface of a majority of cortical 
thymocytes, whereas antigens of CD1 family are expressed 
on a subset of B cells,  dendritic cells of lymph nodes and 
spleen, and Langerhans cells of epidermis as well as cortical 
thymocytes (6-8). Third, anti-JL1 antibody did not react with 
mouse L cells transfected with full-length cDNA of CDla, 
CDlb,  and CDlc  (data not shown). 
It is also very unlikely that JL1 belongs to known activation 
molecules since there are no reactivities in activated periph- 
eral lymphocytes stimulated with PHA, PWM, and anti-CD3 
antibody (Table 1), and the JL1 antigen expression pattern 
is different from that of activation antigens on thymocytes 
reported elsewhere, such as CD25, CD30, CD69, and CD71 
(9-11). JL1  antigen was also clearly different from Thy-1, 
peanut agglutinin receptor, or nonclassical  MHC class I an- 
tigen, in view of the expression pattern within the thymus 
and molecular size (12-14).  Although non-/~2m-associated 
thymocyte differentiation antigens were described by using 
alloantisera procured from multiparous women (15), it was 
very difficult to compare JL1 with them because of a quan- 
titative limit of the alloantisera. 
Specificity for stage II cortical thymocytes was further sup- 
ported by results of the comparative analysis with two-color 
flow cytometry between JLI+ / -  and CDla +/-  thymocytes 
(Fig.  3) and by results of single-color flow cytometric anal- 
ysis of a few leukemic T cell lines which are individually rep- 
resentative of the corresponding stages of thymocyte devel- 
opment (Table 2; 16). On two-color FACS  |  analysis, nearly 
all the thymocytes that were selected by the reactivity to anti- 
JL1 mAb coexpressed CD4 and CD8, and some populations 
were single positive. Further, when screened on several tumor 
cell lines, the most prominent expression was seen in Molt-4 
and Molt-3 cell lines which coexpress both CD4 and CD8 
differentiation antigens, whereas mature T cell lines, Hut-78 
and H9, were negative for JL1 antigen. CCRF-CEM,  a T 
cell line representative of later stage II,  also expressed JL1 
antigen, but proportions ofJI.1 + cells and mean fluorescence 
intensity were lower than those of earlier stage II tumor cell 
lines (Molt-3 and Molt-4). These data indicated that JL1 an- 
tigen was confined to stage II thymocytes and seemed to en- 
compass a wider range of thymic stage II than CDla, CDlb, 
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however, the expression of  both types of antigens largely over- 
lapped and was mostly present in double positive thymocytes, 
except for the slightly different pattern of expression in the 
CD8 single positive subset. This finding was confirmed with 
a flow cytometric analysis of  JL1- and CDla-negative subsets 
which were obtained after panning with both types of mAbs. 
Populations of CD8 single positive subsets were smaller in 
JL-1 negative thymocytes than that of CDla negative cells 
in number. 
In summary, JL1 antigen appears to be a novel thymic stage 
II T cell differentiation marker with the approximate molec- 
ular mass of 120-130 kD.  Further  studies including  more 
detailed biochemical and molecular characterization and func- 
tional  aspects of this molecule are currently underway. 
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